Preclinical data showed that single-agent LB101, PD-L1xCD47 LockBody, delivered systemically led to meaningful tumor regressions and was well toleratedBOSTON and LONDON, June 05, 2022 (GLOBE NEWSWIRE)
Preclinical data showed that single-agent LB101, PD-L1xCD47 LockBody, delivered systemically led to meaningful tumor regressions and was well tolerated.
Investegate announcements from Centessa Pharmaceuticals plc, Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting
Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Centessa Pharmaceuticals (NASDAQ:CNTA – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Thursday, Zacks.com reports. According to Zacks, “Centessa Pharmaceuticals plc is a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients. […]